Expression and inhibitory role of TIMP-3 in hepatocellular carcinoma

BO SHEN1, YINGJIE JIANG1, YUAN-RAN CHEN2, HUI-CONG ZHENG1, WEI ZENG1, YU-YUAN LI1, AOXIAN YIN1 and YUQIANG NIE1

1Department of Gastroenterology and Hepatology, Guangzhou First People's Hospital, Guangzhou Medical University; 2Department of Gastroenterology, Guangzhou Red Cross Hospital, Ji'nan University, Guangzhou, Guangdong 510180, P.R. China

Received January 28, 2016; Accepted March 4, 2016

DOI: 10.3892/or.2016.4818

Abstract. As a member of the tissue inhibitor of metalloproteinases (TIMP) family, it has been reported that TIMP-3 is involved in human cancer development. However, the function of TIMP-3 in hepatocellular carcinoma (HCC) development is unclear. We aimed to determine the biological role of TIMP-3 in HCC by evaluating the effects of its methylation status and expression on HCC cell function. TIMP-3 expression in HCC tissues was visibly analyzed by immunohistochemistry. Methylation of the TIMP-3 promoter was evaluated by methylation-specific PCR. Effects of TIMP-3 on HCC cell growth, apoptosis, migration, and invasion were examined by transfecting the TIMP-3-expressing plasmid, pCMV6. TIMP-3 was expressed in non-tumorous liver tissue, but silenced or down-regulated in 60% of HCC cases (P<0.05). Reduced protein expression of TIMP-3 was associated with reduced tumor differentiation (P=0.003) and increased metastatic activity (P=0.005) in HCC cell lines. Promoter methylation contributed to the TIMP-3 inactivation. Overexpression of TIMP-3 in HCC cell lines suppressed cell proliferation, induced apoptosis, and inhibited migration and invasion in vitro. TIMP-3 expression is suppressed by promoter methylation in HCC. This inhibitory protein acts as a functional tumor suppressor by inhibiting HCC cell proliferation, invasion, and migration and by inducing apoptosis and cell cycle arrest at the G2/M phase.

Introduction

Hepatocellular carcinoma (HCC) is one of the most malignant cancers, which accounts for almost 80% of all primary liver tumors (1). Despite effective surgical and drug therapy for HCC, such as surgical resection, partial melting and intervention, chemoradiotherapy, and other comprehensive treatment, the 5-year survival rate for HCC still remains very low. This high mortality rate is attributable mainly to tumor recurrence and metastases (2). Even with liver transplantation, the prognosis remains poor, owing to persistent tumor recurrence. Thus, there is a compelling need for a novel and specific therapeutic target.

Human tissue inhibitor of metalloproteinase-3 (TIMP-3), located on chromosome 22q12 (3) is an endogenous inhibitor of matrix metalloproteinases (MMPs), including metalloproteinases that have a disintegrin and metalloproteinase (ADAM) domain, and ADAMs with thrombospondin (TS)-like domains. These enzymes play important roles in degrading extracellular matrix (ECM) substrates (4). Unlike other TIMP variants (TIMP-1, 2, and 4), TIMP-3 has poor aqueous solubility and is a component of the ECM (5). Studies have demonstrated that TIMP-3 might function as a potential tumor suppressor gene through induction of tumor cell apoptosis, prevention of tumor ECM remodeling, and inhibition of tumor-derived angiogenic activity (5,6).

The expression of TIMP-3 is silenced in various types of malignant carcinoma (7). Regulation of TIMP-3 may be influenced by many upstream and downstream transcription factors. The type II nuclear receptor, peroxisome proliferator-activated receptor gamma, can upregulate TIMP-3 expression, which can be detected by cDNA microarray and chromatin immunoprecipitation coupled to PCR (8). Transcriptional reprogramming of tumors by overexpression of dormancy-associated microRNAs (DmiRs), particularly DmiR-580, 588, or 190, led to downregulation of TIMP-3 (9). Many other miRs can downregulate TIMP-3 expression, such as miR-21 (10), miR-103 (11), miR-181b (12), miR-181a (13), and miR-221/222 (14). These miRs all regulate TIMP-3 expression by targeting mRNAs at the 3'-untranslated regions (UTRs) for cleavage or translational repression. Thus, miR inhibition can significantly upregulate TIMP-3 protein expression in cancer cells (11).

Another mechanism by which TIMP-3 expression is regulated is the methylation of CpG islands in the TIMP-3 promoter, which results in a dramatic decrease in TIMP-3 mRNA levels (15,16). Ten-eleven translocation methylcyto-
sine dioxygenase 1, encoded by the gene, TET1, has been shown to suppress tumor growth by downregulating TIMP-3 methylation (17). Masson et al showed that loss of TIMP-3 expression in clear cell renal cell carcinoma results from multiple mechanisms, including promoter hypermethylation. Methylation-associated inactivation of TIMP-3 has been reported in bladder cancer and in esophageal and gastric adenocarcinomas as well as renal cancer, and it is associated with poor tumor differentiation, high incidence of tumor invasiveness, and poor clinical outcome (18-20).

Invasion and metastasis of tumor cells are the key characteristics of malignant tumors. By binding to MMPs, in tumor cells, TIMP-3 inhibits their ECM-degrading activity, and thus TIMP-3 is crucially involved in the balance between synthesis and degradation of the ECM, a process which is closely related to tumor cell invasion and metastasis (21). Furthermore, the balance between MMPs and TIMPs is strongly linked to cellular proliferation, apoptosis, and cell cycle arrest as well as invasion and metastasis (22). The activities of both MMP-2, which can promote αvβ3 integrin-mediated adhesion and migration by cleaving fibronectin (23), and MMP-9, which can induce cleavage of the cell-cell/cell-matrix adhesion molecule, CD44 (24), plays an important role in increasing the migration and/or invasion potential of several kinds of cancer cells. Downregulation of the gene that codes for a proliferation-inducing ligand (APRIL), which is typically overexpressed in most tumor cells, leads to reduced expression of MMP-2 and MMP-9 and enhancement of TIMP-3 and TIMP-4 expression (4).

It has been reported that suppression of MMP-9 can inhibit tumor invasion and migration via activating transforming growth factor-β (25), and loss of TIMP-3 expression can result from inactivation of transforming growth factor-β receptor II (18). Recent studies have also shown that TIMP-3 suppresses tumor invasion via the TNFα/NF-κB/IL-6 pathway (16). We have previously found that the transcription factor, peroxisome proliferator activated receptor gamma, partially inhibits HCC cell invasiveness and metastasis via binding directly to the TIMP-3 promoter and upregulating TIMP-3 protein expression (8).

Although TIMP-3 has been shown to inhibit tumor growth, invasion, and metastasis (26), the effects of this physiological inhibitor in HCC have not been fully characterized. In this study, our aim was to assess the methylation status of the TIMP-3 promoter and expression of TIMP-3 in HCC and elucidate the biological function of TIMP-3 in HCC by exogenously inducing TIMP-3 expression in liver cancer cells.

Materials and methods

Patient tissue samples. Tissue samples embedded in paraffin blocks were obtained from the livers of 80 HCC patients and 60 cancer-free patients (control subjects). None of these patients had received any other therapeutic intervention prior to surgery. Pertinent demographic and clinicopathological data, such as gender, age, tumor size, hepatitis B virus (HBV) infection, liver cirrhosis, tumor pathological grade, lymph node metastasis, and distant metastasis were collected for further analyses. The study protocol was approved by the Clinical Research Ethics Committee of Guangzhou Medical University.

Immunohistochemistry (IHC). IHC staining was performed on 4-µm-thick paraffin sections using the TIMP-3 primary antibody (1:100 dilution; Santa Cruz Biotechnology, Dallas, TX, USA). Sections were washed in Tris-buffered saline and stained in a two-step process involving incubation with a horse-radish peroxidase-conjugated antibody kit (1:2000 dilution, Santa Cruz Biotechnology), followed by incubation with the chromagen, 3,3′-diaminobenzidine (Dako, Glostrup, Denmark). TIMP-3 immunostaining was defined according to the intensity and percentage of TIMP-3- positive tumor cells. The staining intensity was scored as follows: 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The percentage of TIMP-3 positive cells was classified into 4 categories: score of 1 for 0-10%, 2 for 11-50%, 3 for 51-80%, and 4 for 81-100%. The degree of TIMP-3 staining was quantified by using a two-level grading system (with the intensity score added to the percentage score to produce a final score), as follows: <3, negative expression; and 3-9, positive expression.

Human HCC cell lines and culture. The human HCC HepG2 cell line was a gift from AiMing Li, Department of Digestive System, Southern Medical University. The human HCC SMMC-7721 cell line was purchased from the Experimental Animal Center of Sun Yat-Sen University. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum in 5% CO₂ at 37°C.

Bisulfite conversion and methylation-specific PCR (MSP). MSP was performed as previously described (16) and was used to examine the DNA methylation status of the TIMP-3 promoter. Genomic DNA was extracted from 8 different HCC cell lines with NucleoSpin Tissue mini spin columns (Macherey-Nagel GmbH & Co. KG, Düren, Germany). Sodium bisulfite modification was performed with the Epitect Bisulfite kit (Qiagen, Hilden, Germany). The primers used in MSP were designed via the MethPrimer web site (http://www.urogene.org/methprimer.html) and synthesized by Invitrogen Custom DNA Oligos (Life Technologies, Grand Island, NY, USA). The sequences of the forward and reverse primers were: MSP forward methylation primer, 5'-TCGAGGATTAGCGGTTAAGTATC-3'; MSP reverse methylation primer, 5'-GAAACAAAAAATAACGAAACGAA-3'; MSP forward non-methylation primer, 5'-TTGAGGATTAGTGTAAGTTTGG-3'; MSP reverse non-methylation primer, 5'-CAAACAAAAATACAAAAACAAAAA-3'. The MSP was performed as previously described (16) and was quantified by real-time PCR. Real-time amplification of 1 µg of cDNA was performed with 12.5 µl of Master SYBR Green Supermix in the CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Amplification was performed, with the target gene mRNA levels being normalized to the expression of GAPDH. Results were analyzed by the 2-ΔCtt method.

Demethylation treatment. Selected methylation-positive HCC cells were cultured with the DNA methyltransferase inhibitor,
5-Aza-CdR, at a concentration of 5 µM or 0 µM (control). Pyrosequencing analysis was performed to examine the effects of 5-Aza-CdR on the methylation level of the TIMP-3 promoter CpG islands in HCC cells. Pyrosequencing was performed by the PyroMark Q96 ID System (Qiagen) as previously described (27).

Plasmids and transfection. HepG2 and SMMC-7721 cells were transfected with the pCMV6-TIMP-3 plasmid, which strongly expresses human TIMP-3 under a CMV promoter. The pCMV6-AC-GFP plasmid was used as the vector control. The open reading frames cloned in this vector are expressed in mammalian cells as a tagged protein (C-terminal tGFP), which can be visualized as green fluorescence under a fluorescence microscope. Since it has been shown that methylation of TIMP-3 in HepG2 is closely associated with TIMP-3 silencing in HCC and because the pCMV6-TIMP-3 plasmid has been successfully transfected into SMMC-7721 cells (28), we selected these cell lines for the transfection experiments. The cells were transfected using MegaTran 1.0 transfection reagent (OriGene, Rockville, MD, USA) according to the manufacturer's instructions. Cells were cultured for 2 weeks with the aminoglycoside, G418 (Thermo Fisher Scientific, Shanghai, China), to select the gene-transfected cells. Most cells are not transfected with the expression plasmid and thus are killed by G418. Those cells that remain growing in this selective medium have retained the expression plasmid, which stably integrates into the genome of the targeted cells. The group of cells transfected with the pCMV6-TIMP-3 plasmid were labeled as TIMP-3, and the group of cells not transfected with this plasmid were labeled as NC (control). The cultures were observed under fluorescence microscopy to confirm the presence of tGFP+ transfected cells, and the transfection efficiency was determined by counting the number of tGFP+ cells.

Western blot assay. Total protein was extracted and protein concentration was measured by the BCA protein assay (Bioworld, Minneapolis, MN, USA). Protein (40 µg) from each sample was used for western blotting as previously described (29). Bands were observed using the Pierce Enhanced Chemiluminescence kit (Thermo Fisher Scientific).

Cell viability assay. Cell proliferation was determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. Cells were cultured for 2 weeks with the aminoglycoside, G418 (Thermo Fisher Scientific, Shanghai, China), to select the gene-transfected cells. Most cells are not transfected with the expression plasmid and thus are killed by G418. Those cells that remain growing in this selective medium have retained the expression plasmid, which stably integrates into the genome of the targeted cells. The group of cells transfected with the pCMV6-TIMP-3 plasmid were labeled as TIMP-3, and the group of cells not transfected with this plasmid were labeled as NC (control). The cultures were observed under fluorescence microscopy to confirm the presence of tGFP+ transfected cells, and the transfection efficiency was determined by counting the number of tGFP+ cells.

Statistical analyses. Data are presented as the mean ± standard deviation (SD). Differences between two groups were analyzed by Student's t-test. The correlation between TIMP-3 positive-expression and liver cancer was analyzed by the Mann-Whitney test. Chi-square tests were performed to evaluate the relationship between TIMP-3 expression and clinicopathological parameters. Statistical analyses were performed in the SPSS package for Windows (version 16.0; SPSS Inc., Chicago, IL, USA). Differences with a P-value <0.05 were considered statistically significant.

Table I. Comparison of TIMP-3 expression between HCC and control subjects.

<table>
<thead>
<tr>
<th>Subjects</th>
<th>TIMP-3-positive</th>
<th>TIMP-3-negative</th>
<th>χ²</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cases</td>
<td>69 (49.29)</td>
<td>71 (50.71)</td>
<td>6.439</td>
<td>0.011</td>
</tr>
<tr>
<td>HCC</td>
<td>32 (40.00)</td>
<td>48 (60.00)</td>
<td>6.439</td>
<td>0.011</td>
</tr>
<tr>
<td>Control</td>
<td>37 (61.67)</td>
<td>23 (38.33)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values represent n (%).
Results

TIMP-3 expression in HCC tissues. As shown in Table I and Fig. 1, TIMP-3 was expressed in only 32 of 80 (40%) HCC tissue samples, whereas 37 of 60 tumor-free samples (61.67%) exhibited TIMP-3 expression (P=0.011). Tissue from 76.67% of younger patients (<50 years) with HCC showed negative TIMP-3 expression, while only 50% of tissues from older patients exhibited negative TIMP-3 expression (P=0.018). Reduced expression of TIMP-3 was correlated with higher frequencies of poorly differentiated carcinomas and metastasis. No significant correlations were observed between TIMP-3 expression and the remaining clinicopathological parameters (Table II).

TIMP-3 gene expression and methylation status in HCC cells. Results of MSP analysis were positive for TIMP-3 promoter methylation in 3 of 8 HCC cell lines: C3A, HepG2, and Hep-3B (Fig. 2A). Thus, we selected these cell lines and treated them with 5-Aza-CdR. As shown in Fig. 2B, TIMP-3 mRNA in all three cell lines was upregulated by demethylation treatment (P<0.05). Results of the pyrosequencing analyses (Fig. 2C) revealed decreased methylation level in all three cell lines after 5-Aza-CdR treatment (P<0.05).

Expression of TIMP-3 plasmid in transfected HCC cells. An illustration of the GFP expression vector is shown in Fig. 3A, and the extent of GFP labeling in SMMC-7721 and HepG2 cells is shown in Fig. 3B. Nearly all the G418-selected cells exhibited green fluorescence. The western blots revealed robust TIMP-3 protein expression in the TIMP-3 group, whereas no protein expression was observed in the NC group (Fig. 3C).

Effects of TIMP-3 overexpression on HCC cell viability, apoptosis, and cell cycle arrest. The MTS assay revealed suppressed growth of SMMC-7721 and HepG2 cells, stably transfected with TIMP-3, in a significant, time-dependent manner (Fig. 4). As shown in Fig. 5A-C, Flow cytometric analysis of Annexin V-FITC/PI revealed an increased mean number of apoptotic cells in the TIMP-3 group compared to the NC group (SMMC-7721: 30.7±1.6% vs. 8.4±1.1%, P<0.01; HepG2: 12.6±1.1% vs. 7.6±1.3%, P<0.05). The flow cytometry results depicted in Fig. 6A, band c revealed an induction of cell cycle arrest in TIMP-3 transfected cells, as evidenced by a decreased mean number of G0/G1 cells compared to that of the NC group (SMMC-7721: 36.08±3.53% vs. 57.72±1.53%, P<0.05; HepG2: 49.82±1.46% vs. 59.47±1.27%, P<0.05) and

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>TIMP-3-positive (%)</th>
<th>TIMP-3-negative (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>0.598</td>
</tr>
<tr>
<td>Male</td>
<td>25 (41.67)</td>
<td>35 (58.33)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>7 (35.00)</td>
<td>13 (65.00)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td>0.018</td>
</tr>
<tr>
<td>&lt;50</td>
<td>7 (23.33)</td>
<td>23 (76.67)</td>
<td></td>
</tr>
<tr>
<td>≥50</td>
<td>25 (50.00)</td>
<td>25 (50.00)</td>
<td></td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td>0.144</td>
</tr>
<tr>
<td>&lt;5 cm</td>
<td>20 (47.62)</td>
<td>22 (52.38)</td>
<td></td>
</tr>
<tr>
<td>≥5 cm</td>
<td>12 (31.58)</td>
<td>26 (68.42)</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td>0.003</td>
</tr>
<tr>
<td>Mod-well</td>
<td>23 (56.10)</td>
<td>18 (43.90)</td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>9 (23.08)</td>
<td>30 (76.92)</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td>0.005</td>
</tr>
<tr>
<td>Yes</td>
<td>11 (25.59)</td>
<td>32 (74.41)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>21 (56.76)</td>
<td>16 (43.24)</td>
<td></td>
</tr>
<tr>
<td>HBV infection</td>
<td></td>
<td></td>
<td>0.205</td>
</tr>
<tr>
<td>Yes</td>
<td>19 (35.19)</td>
<td>35 (64.81)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>13 (50.00)</td>
<td>13 (50.00)</td>
<td></td>
</tr>
<tr>
<td>Fatty liver</td>
<td></td>
<td></td>
<td>0.059</td>
</tr>
<tr>
<td>Yes</td>
<td>4 (80.00)</td>
<td>1 (20.00)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>28 (37.33)</td>
<td>47 (62.67)</td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td></td>
<td></td>
<td>0.923</td>
</tr>
<tr>
<td>Yes</td>
<td>21 (39.62)</td>
<td>32 (60.38)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>11 (40.74)</td>
<td>16 (59.26)</td>
<td></td>
</tr>
</tbody>
</table>
Figure 2. TIMP-3 gene expression and promoter methylation in HCC cell lines. (A) Representative agarose gel showing TIMP-3 promoter DNA bands in 8 HCC cell lines. M, PCR specific for methylated DNA; U, PCR specific for unmethylated DNA. (B) Relative TIMP-3 gene expression in response to 5-Aza-CdR in 3 HCC cell lines. *P<0.05 vs. untreated group. (C) Methylation level in response to 5-Aza-CdR in the same HCC cell lines. *P<0.05 vs. untreated group.

Figure 3. Expression of transfected TIMP-3 gene in HCC cells. (A) Vector map of pCMV6-AC-GFP plasmid. (B) Representative fluorescence (left) and nonfluorescence (right) photomicrographs of tGFP® positive SMMC-7721 and HepG2 cells transfected with TIMP-3 plasmid. Cells appear as fluorescent green dots in fluorescence photomicrograph. Magnification, x100. (C) Representative western blots showing expression of TIMP-3 protein in the following lanes: 1, SMMC-7721, TIMP-3 group; 2, SMMC-7721, NC group; 3, HepG2, TIMP-3 group; 4, HepG2, NC group. β-actin was used as the loading control.

Figure 4. Time course of cell viability measured as MTS reduction in TIMP-3-transfected SMMC-7721 (A) and HepG2 (B) cells. *P<0.05 vs. NC group at day 3. **P<0.01 vs. NC group at day 5.
an increased mean number of G2/M cells compared to that of
the NC group (SMMC-7721: 51.91±1.71% vs. 30.11±0.20%,
P<0.05; HepG2: 26.27±0.54% vs. 14.15±3.61%, P<0.05).

Effect of TIMP-3 on SMMC-7721 and HepG2 invasion and
migration. The number of cells penetrating through the
Matrigel membrane reflects the cell invasion ability. As shown
in Fig. 7A, the mean number of TIMP-3-transfected invading
cells was lower compared to that of the NC group (SMMC-
7721: 60±11 vs. 121±17, P<0.05; HepG2: 98±6 vs. 192±22,
P<0.05). Results of the migration assay (Fig. 7B) revealed a
lower mean number of TIMP-3 transfected migrating cells
compared to that of the NC group (SMMC-7721: 53±8 vs.
102±10, P<0.01; HepG2: 109±9 vs. 232±13, P<0.01).
Discussion

In this study, we characterized the methylation status of the TIMP-3 promoter in HCC cells and have examined the effects of TIMP-3 promoter methylation and TIMP-3 expression on several parameters of HCC cell function. The results from our study allow us to elucidate the biological role of TIMP-3 in HCC and the molecular basis for the TIMP-3 effects on HCC cells. We found decreased TIMP-3 expression in a significant number of tissue samples from patients with HCC. Methylation status of the TIMP-3 promoter was positive in three HCC cell lines (C3A, HepG2, and Hep-3B), and the expression of TIMP-3 mRNA significantly increased after demethylation with 5-Aza-CdR. These results indicate that TIMP-3 expression in HCC is downregulated, and the mechanism responsible for this downregulation, at least in part, is methylation of the TIMP-3 promoter. These findings are similar to those of other studies that revealed methylation of TIMP-3 in brain, lung, kidney, colorectal, and other tumors (7,30,31).

To determine whether TIMP-3 has antitumor activity in HCC, we upregulated TIMP-3 expression in HCC cells via gene transfection. After incubation with selective media, nearly all the remaining cells expressed tGFP, as evidenced by the observed green fluorescence. This indicates that the TIMP-3 plasmid was transfected with relatively high efficiency. These transfected HCC cells exhibited robust expression of TIMP-3 protein, which was associated with decreased cell proliferation. Upregulation of TIMP-3 expression results in significantly increased expression of cyclin-dependent kinase inhibitor, p27 (30). It has been shown that p27, by binding to and inhibiting cyclin-cyclin-dependent kinase complexes directly involved in cell cycle control (31,32), is a key inhibitor of cell proliferation. The loss of p27 expression promotes hepatocarcinogenesis through STAT3 signaling activation (33).

Along with reduced cell proliferation, we also observed a significant increase in apoptosis in TIMP-3 transfected HCC cells. There are two major apoptotic pathways that cells can follow: the extrinsic Fas death receptor-mediated pathway and the intrinsic, mitochondrial-associated caspase-dependent pathway. Binding of the Fas receptor to its ligand (Fas-L) can trigger a signaling cascade via the intrinsic caspase-dependent pathway that results in apoptosis (34,35), and it has been shown that TIMP-3 can induce this intrinsic apoptotic pathway that is initiated via the extrinsic Fas-associated mechanism (17). Another study demonstrated that increased expression of TIMP-3, via silencing the APRIL gene, leads to decreased expression of the antiapoptotic proteins, Bcl-2 and Bcl-xL, and increased expression of the proapoptotic protein, Bax (36). Additional evidence suggests that TIMP-3-induced upregulation of p27 can result in increased expression of apoptosis-related proteins (33).

We used flow cytometry analysis to evaluate the effects of TIMP-3 on cell cycling. The decreased number of G0/G1 and increased number G2/M TIMP-3-transfected HCC cells suggest that TIMP-3 can induce G2/M phase arrest, with a concomitant reduction in cellular proliferation. G2/M arrest by TIMP-3 is linked to p53, which controls the entry of cells into the mitosis phase at the G2 checkpoint (37). Cells prepare for
mitosis by increasing the level of cyclin B1 and activating Cdc2, the cyclin-dependent kinase required to enter mitosis (36). The mechanism by which p53 blocks entry into the mitosis phase partly involves inhibition of Cdc2 by several transcription factors: p21, 14-3-3-σ, and Gadd45. p21 can bind to and inhibit the cyclin B1/Cdc2 complex, thereby inactivating Cdc2 (38). When the cyclin B1-Cdc2 complexes are inactivated, the cells are arrested in the G1/M phase (39).

Invasion and migration ability are typical features of HCC and other malignant cell types. Compared to non-transfected cells, we observed significantly lower numbers of transfected HCC cells that were able to penetrate through the Matrigel and cross the membrane to the lower chamber. These results indicate that increased expression of TIMP-3 suppresses the HCC cell ability to metastasize and invade surrounding tissues. As observed for other kinds of malignant tumors, our study provides evidence that TIMP-3 has antitumor activity against HCC and that TIMP-3 may exert this antitumor activity via multiple mechanisms.

Having observed the TIMP-3 protein expression and suppressive function clinically and in vitro, we plan to explore the molecular mechanism underlying the inhibitory effect of TIMP-3 on HCC in our next project. TIMP-3 is considered a tumor suppressor gene that may be capable of upregulating other antitumorigenic genes. Thus, the precise downstream pathways by which it mediates such effects are worthy of future studies.

In conclusion, TIMP-3 can act as a tumor-suppressor gene in HCC. TIMP-3 is expressed at low levels in HCC, but its expression can be activated by treatments with demethylation agents, such as 5-Aza-CdR. TIMP-3 exerts its anticancer effects on HCC via suppressing cell proliferation, inducing apoptosis and G1/M phase arrest, and inhibiting invasion and migration.

Acknowledgements

The study was supported by the National Natural Science Foundation of China (no. 81270037), the Research Fund for the Doctoral Program of Higher Education of China (no. 20114423110005) and Medical Scientific Research Foundation of Guangdong Province (no. A2014550).

References

3. Yu WH, Yu S, Meng Q, Brew K and Woessner JF jr: TIMP-3 on HCC in our next project. TIMP-3 is considered a tumor suppressor gene that may be capable of upregulating other antitumorigenic genes. Thus, the precise downstream pathways by which it mediates such effects are worthy of future studies.

In conclusion, TIMP-3 can act as a tumor-suppressor gene in HCC. TIMP-3 is expressed at low levels in HCC, but its expression can be activated by treatments with demethylation agents, such as 5-Aza-CdR. TIMP-3 exerts its anticancer effects on HCC via suppressing cell proliferation, inducing apoptosis and G1/M phase arrest, and inhibiting invasion and migration.

Acknowledgements

The study was supported by the National Natural Science Foundation of China (no. 81270037), the Research Fund for the Doctoral Program of Higher Education of China (no. 20114423110005) and Medical Scientific Research Foundation of Guangdong Province (no. A2014550).

References

3. Yu WH, Yu S, Meng Q, Brew K and Woessner JF jr: TIMP-3 on HCC in our next project. TIMP-3 is considered a tumor suppressor gene that may be capable of upregulating other antitumorigenic genes. Thus, the precise downstream pathways by which it mediates such effects are worthy of future studies.

In conclusion, TIMP-3 can act as a tumor-suppressor gene in HCC. TIMP-3 is expressed at low levels in HCC, but its expression can be activated by treatments with demethylation agents, such as 5-Aza-CdR. TIMP-3 exerts its anticancer effects on HCC via suppressing cell proliferation, inducing apoptosis and G1/M phase arrest, and inhibiting invasion and migration.

Acknowledgements

The study was supported by the National Natural Science Foundation of China (no. 81270037), the Research Fund for the Doctoral Program of Higher Education of China (no. 20114423110005) and Medical Scientific Research Foundation of Guangdong Province (no. A2014550).

References

3. Yu WH, Yu S, Meng Q, Brew K and Woessner JF jr: TIMP-3 on HCC in our next project. TIMP-3 is considered a tumor suppressor gene that may be capable of upregulating other antitumorigenic genes. Thus, the precise downstream pathways by which it mediates such effects are worthy of future studies.

In conclusion, TIMP-3 can act as a tumor-suppressor gene in HCC. TIMP-3 is expressed at low levels in HCC, but its expression can be activated by treatments with demethylation agents, such as 5-Aza-CdR. TIMP-3 exerts its anticancer effects on HCC via suppressing cell proliferation, inducing apoptosis and G1/M phase arrest, and inhibiting invasion and migration.

Acknowledgements

The study was supported by the National Natural Science Foundation of China (no. 81270037), the Research Fund for the Doctoral Program of Higher Education of China (no. 20114423110005) and Medical Scientific Research Foundation of Guangdong Province (no. A2014550).

References

3. Yu WH, Yu S, Meng Q, Brew K and Woessner JF jr: TIMP-3 on HCC in our next project. TIMP-3 is considered a tumor suppressor gene that may be capable of upregulating other antitumorigenic genes. Thus, the precise downstream pathways by which it mediates such effects are worthy of future studies.

In conclusion, TIMP-3 can act as a tumor-suppressor gene in HCC. TIMP-3 is expressed at low levels in HCC, but its expression can be activated by treatments with demethylation agents, such as 5-Aza-CdR. TIMP-3 exerts its anticancer effects on HCC via suppressing cell proliferation, inducing apoptosis and G1/M phase arrest, and inhibiting invasion and migration.

Acknowledgements

The study was supported by the National Natural Science Foundation of China (no. 81270037), the Research Fund for the Doctoral Program of Higher Education of China (no. 20114423110005) and Medical Scientific Research Foundation of Guangdong Province (no. A2014550).

References

3. Yu WH, Yu S, Meng Q, Brew K and Woessner JF jr: TIMP-3 on HCC in our next project. TIMP-3 is considered a tumor suppressor gene that may be capable of upregulating other antitumorigenic genes. Thus, the precise downstream pathways by which it mediates such effects are worthy of future studies.

In conclusion, TIMP-3 can act as a tumor-suppressor gene in HCC. TIMP-3 is expressed at low levels in HCC, but its expression can be activated by treatments with demethylation agents, such as 5-Aza-CdR. TIMP-3 exerts its anticancer effects on HCC via suppressing cell proliferation, inducing apoptosis and G1/M phase arrest, and inhibiting invasion and migration.


